What Does an Ophthalmic Surgical Device Cost?

Capital equipment pricing across phacoemulsification, femtosecond laser, vitreoretinal, and MIGS platforms — based on publicly listed secondary-market prices, manufacturer announcements, and FDA regulatory filings. MedSource does not yet have aggregate quote data for this category; this article will be updated as quotes accrue.

---

Ophthalmic surgical devices span a wider price range than almost any other OR capital equipment category — from a $5,000 manual instrument set to a femtosecond laser platform that can exceed $500,000. The category broadly covers four capital-intensive platforms: phacoemulsification (phaco) systems for cataract surgery, femtosecond laser-assisted surgical systems (FLACS), vitreoretinal combined consoles, and energy-based glaucoma devices including MIGS implant delivery systems. The market includes energy-based phacoemulsification and femtosecond laser-based systems for cataract emulsification, as well as laser systems to treat glaucoma, vitreoretinal disease, or correct vision in LASIK procedures. What you pay depends most heavily on platform generation, modal capability (single-function vs. combined anterior/posterior), FDA classification, and whether the system is purchased new, certified-refurbished, or leased. Manufacturer list prices for flagship systems are not published; the figures below are drawn from secondary markets, public filings, and distributor listings — and should be treated as directional benchmarks, not binding quotes.

---

What the Typical Range Is

New phacoemulsification devices cost from $30,000 to $150,000, depending on brand, configuration, and level of technological complexity — with modern devices featuring automatic parameter adjustment, visualization, and heating systems commanding the highest prices.

On the secondary market, phacoemulsifiers typically cost between $15,000 and $70,000 depending on condition — an alternative well-suited to clinics with limited budgets or newer institutions.

Combined vitreoretinal-cataract consoles occupy the higher tier of the range. Alcon's UNITY® VCS — which received FDA 510(k) clearance in 2024 and integrates both anterior segment phacoemulsification and posterior segment vitreoretinal surgery into a single platform — does not carry a publicly listed price, but comparable combined systems from previous generations have traded in the $150,000–$350,000 range on distributor and auction markets. Femtosecond laser platforms for laser-assisted cataract surgery (LACS) and LASIK are the highest-cost line item; publicly verifiable secondary-market listings place refurbished excimer and femtosecond systems between $200,000 and $500,000. Manufacturer list prices for current-generation systems (Alcon LenSx, Zeiss VisuMax, Bausch + Lomb TENEO) are not published. Bausch + Lomb's TENEO Excimer Laser Platform, which received FDA approval in early 2024, is designed for LASIK surgery in patients with myopia — but no list price has been publicly disclosed.

Cataract systems represented 41.6% of the ophthalmic surgical devices market in 2024, anchored by more than 20 million annual procedures worldwide , making phaco consoles the highest-volume capital purchase in this space.

Device Type	New (Est.)	Certified Refurbished (Est.)
Phacoemulsification console	$30,000 – $150,000	$15,000 – $70,000
Combined phaco/vitreoretinal system	$150,000 – $350,000+	$80,000 – $200,000
Femtosecond / excimer laser platform	$350,000 – $500,000+	$150,000 – $300,000
MIGS delivery system console	$20,000 – $60,000	$10,000 – $30,000

Ranges are derived from secondary-market listings and public distributor data; GSA pricing and manufacturer list prices are not publicly available for most flagship systems.

---

What Pushes Price Up — Features, Certifications, Support Tier

Platform integration. Alcon's Unity VCS integrates vitreoretinal and cataract functions into a common console, advancing workflow synergy and creating lock-in at high-volume centers — and commands a corresponding premium over single-function systems.

Advanced fluidics. Advanced fluidics platforms such as Alcon's CENTURION Vision System with ACTIVE SENTRY maintain more physiologic intraocular pressure, decreasing endothelial cell loss and expediting recovery — features that justify a price step-up over baseline phaco consoles.

Regulatory class. Class II devices such as surgical lasers and intraocular injection tools require 510(k) clearance to confirm substantial equivalence , while Class III implantable devices like IOLs and artificial corneas require full Pre-Market Approval (PMA), including clinical data to validate safety and effectiveness — and the compliance costs are reflected in acquisition price.

Electrical safety certifications. Systems sold in the U.S. must comply with IEC 60601-1, IEC 60601-2-2, and IEC 80601-2-58 for electrical safety, and EN 60601-1-2 / 47 CFR Part 15 Subpart B for EMC — add-ons that increase both manufacturing and testing cost.

Digital workflow modules. Digital workflow suites that bundle biometry, formula calculators, and cloud data transfer elevate throughput and surgeon consistency , but add $15,000–$40,000 to console pricing when bundled.

Market concentration. The top five manufacturers — Alcon, Johnson & Johnson Vision Care, Carl Zeiss Meditec, Bausch + Lomb, and Glaukos — controlled roughly 65% of 2024 revenue , which limits competitive downward pressure on flagship system pricing.

---

What Pushes Price Down — Refurbished, Older Generation, Lease, GPO Contracts

Certified refurbished. The secondary market for phaco consoles is liquid. Phacoemulsifiers on the secondary market typically cost between $15,000 and $70,000 depending on condition — an excellent alternative for clinics with limited budgets or small institutions. Verify OEM certification status and remaining handpiece cycle counts before purchase.

Older generation. Predecessor models (e.g., Alcon CENTURION vs. UNITY, Zeiss Visalis 100 vs. Visalis S500) retain clinical viability for straightforward cataract cases. Procurement officers buying one generation behind current flagship can often negotiate 30–40% off current-generation pricing.

Regional competition. A growing number of regional manufacturers, particularly in China and India, are increasing their presence by offering competitively priced equipment to meet local demand — and these units are increasingly appearing in U.S. ASC tenders. Evaluate FDA clearance status carefully before considering non-OEM alternatives.

GPO contracts. Vizient, Premier, and HealthTrust maintain vendor agreements for ophthalmic capital equipment. Activation of an existing GPO contract typically yields 10–18% off list for phaco consoles; savings are lower for femtosecond laser systems where leverage is more limited.

Lease or usage-based models. Several manufacturers offer per-procedure pricing or operating lease structures, shifting capex to opex. This is particularly common for femtosecond laser platforms where the acquisition cost is prohibitive for lower-volume ASCs.

---

Hidden Costs — Install, Training, Calibration, Consumables, Service Contracts

Consumables lock-in. Phaco handpieces, irrigation/aspiration tubing sets, vitrectomy packs, and IOL injectors are proprietary to most platforms. The core phacoemulsification system consists of a console, a handpiece with a titanium needle, an irrigation-aspiration system, and sophisticated fluidics — all components with recurring per-case costs. Budget $150–$400 per cataract case in disposable consumables depending on the platform and procedure complexity.

IOL costs. IOLs are a separate line item entirely. Premium toric and multifocal IOLs from major manufacturers run $300–$600 per lens for institutional buyers; extended depth-of-focus (EDOF) models sit at the top of that range or above. Standard monofocal IOLs are significantly cheaper.

Service contracts. Annual service agreements for phaco consoles typically run 8–12% of acquisition price. For a $100,000 console, that translates to $8,000–$12,000/year. Femtosecond laser platforms, due to optical alignment requirements, typically carry 10–15% annual service costs.

Installation and qualification. Complex laser platforms require facility preparation (vibration-dampened flooring, dedicated electrical circuits, temperature-controlled rooms), optical alignment, and IQ/OQ/PQ validation. Facility prep alone can add $10,000–$50,000 before the system generates its first case.

Staff training. Key features of phacoemulsification systems — including fluidics control, ultrasound modulation, user interface, and instrument compatibility — require structured operator training . OEM-provided training is sometimes included in purchase price for the first cohort; subsequent staff training is typically billed at $1,500–$5,000 per session.

---

How to Negotiate — Concrete Tactics

1. Request itemized line pricing. Separate console hardware, handpieces, software licenses, installation, and first-year service. Bundled pricing obscures where margin lives; unbundling it gives you leverage on specific line items.

2. Use competitive bids as floor, not ceiling. Obtain quotes from at least three vendors — including at least one certified-refurbished option — before entering final negotiation. Sharing a competing quote during negotiations routinely moves console pricing 10–20%.

3. Negotiate consumables pricing upfront. Lock in per-case pricing for tubing sets and handpiece tip kits at time of capital purchase. Multi-year consumables agreements bundled with the capital purchase can yield 15–25% savings on per-case costs over the contract life.

4. Leverage end-of-fiscal-quarter timing. Ophthalmic capital sales reps operate on quarterly and annual quotas. Late-Q3 and late-Q4 submissions reliably produce better discounts.

5. Push for extended warranties in lieu of list price reductions. If a vendor won't move on console price, negotiate 24-month warranties (vs. standard 12-month), free software upgrades, or loaner coverage during downtime — all of which have quantifiable value.

6. Engage your GPO. Medicare's 2.9% ASC fee boost for 2025 and sustained capital budgets at leading academic centers anchor the regional procurement environment — use that leverage to activate GPO pricing on capital equipment before approaching manufacturers directly.

---

When the Price Feels Off — Red Flags

• A phaco console quoted below $12,000 new without a verifiable FDA 510(k) clearance number should trigger immediate due diligence. Cross-reference the clearance number against the FDA 510(k) database.
• No IEC 60601-1 or IEC 80601-2-58 documentation. Any surgical phaco system lacking electrical safety certification documentation for the U.S. market is a compliance liability.
• Consumables exclusivity without transparency. If a vendor cannot specify per-case consumable costs in writing at time of capital purchase, the total cost of ownership model is incomplete.
• Refurbished systems without OEM or ISO 13485–certified refurbishment documentation. Unverified refurbishment histories are a patient safety and accreditation risk. Request service history and biocompatibility test compliance with ISO 10993.
• A vendor claiming "no service contract needed" for a femtosecond or vitreoretinal laser platform. All laser systems require periodic optical calibration and preventive maintenance; any quote that omits service is not a full cost picture.

---

Sources

1. FDA 510(k) Database & 21 CFR Part 886 — Regulatory classification framework for ophthalmic devices (Class I/II/III), eCFR and FDA accessdata. accessdata.fda.gov
2. FDA 510(k) Clearance Letter K213467 — D.O.R.C. EVA NEXUS Ophthalmic Surgical System; IEC 60601-1 / IEC 80601-2-58 compliance documentation. FDA accessdata
3. Alcon Investor Relations / Business Wire (June 2024) — UNITY® VCS and UNITY® CS FDA 510(k) clearance announcement. businesswire.com
4. Bimedis Secondary Market Listings (2024–2025) — Publicly listed used and pre-owned phacoemulsification system pricing. bimedis.com
5. Mordor Intelligence: Ophthalmology Surgical Devices Market (2025) — Market share, growth rates, and end-user segmentation data. mordorintelligence.com

---

This article reflects publicly available pricing data as of May 2025. MedSource will update it with aggregated quote data as submissions are received. Pricing should be verified against current vendor quotes and applicable GPO contracts before any procurement decision.